I. A. Zaigrayev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
I. A. Zaigrayev has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Anastasia Doronenkova
S.S. Yudin City Clinical Hospital, Moscow, Russia
6 shared publications - Nikolay Krotenko
S.S. Yudin City Clinical Hospital, Moscow, Russia; Russian Medical Academy of Continuous Professional Education, Moscow, Russia
6 shared publications - Marina Grinenko
S.S. Yudin City Clinical Hospital, Moscow, Russia
5 shared publications - N. S. Pokrovskiy
National Medical Research Center of Cardiology named after academician Eugene Chazov, Moscow, Russia
5 shared publications - Olga Viktorovna Ignatenko
Sergey Yudin City Clinical Hospital, Moscow, Russia;Russian Medical Academy of Continuous Professional Education, Moscow, Russia;Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
5 shared publications - Anastasia Marysheva
S.S. Yudin City Clinical Hospital, Moscow, Russia
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Science Publishing Group in International Journal of Clinical and Experimental Medical Sciences
- Vol. 12 (5) , 82-95
Prognostic Role of Nucleosomes Containing Histones of the H3.1 Type in Septic Shock: Results of a Prospective Study
Cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs), specifically marked by histone type 3.1, play a dual pathogenic role in sepsis by reflecting cellular damage and directly exacerbating tissue injury, highlighting their clinical relevance for extracorporeal elimination therapies. To evaluate their prognostic value, we conducted a prospective, single-center observational study quantifying nucleosomes containing histones of the H3.1 type (Nu.H3.1) in 52 adult patients with septic shock admitted to an intensive care unit between August 2023 and May 2024. The cohort (64% male) had a mean SOFA score of 10±4 and an APACHE II score of 22±7. The H3.1-nuc concentration was 4658 ± 3962 ng/mL, and the median cfDNA level was 3041 (876–7815) ng/mL. Statistical analysis revealed that Nu.H3.1 levels significantly and positively correlated with cfDNA (r=0.67; p=0.0001), serum lactate (r=0.4; p=0.004), and SOFA scores (r=0.41; p=0.002). Furthermore, Nu.H3.1 demonstrated significant predictive performance for both 28-day mortality (AUC=0.68; 95% CI: 0.53–0.84; p=0.037) and the development of acute kidney injury (AKI) (AUC=0.74; 95% CI: 0.57–0.90; p=0.014). In conclusion, Nu.H3.1 serves as an independent predictor of adverse outcomes in septic shock, with established threshold values identifying patients at high risk for mortality and AKI. These findings suggest that Nu.H3.1 is a promising biomarker for clinical risk stratification and for substantiating indications for the extracorporeal elimination of toxic DNA-associated structures from the systemic circulation.
- 23 October 2026
- Published by Science Publishing Group in International Journal of Clinical and Experimental Medical Sciences
- Vol. 12 (5) , 82-95
Open AccessPrognostic Role of Nucleosomes Containing Histones of the H3.1 Type in Septic Shock: Results of a Prospective Study
Cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs), specifically marked by histone type 3.1, play a dual pathogenic role in sepsis by reflecting cellular damage and directly exacerbating tissue injury, highlighting their clinical relevance for extracorporeal elimination therapies. To evaluate their prognostic value, we conducted a prospective, single-center observational study quantifying nucleosomes containing histones of the H3.1 type (Nu.H3.1) in 52 adult patients with septic shock admitted to an intensive care unit between August 2023 and May 2024. The cohort (64% male) had a mean SOFA score of 10±4 and an APACHE II score of 22±7. The H3.1-nuc concentration was 4658 ± 3962 ng/mL, and the median cfDNA level was 3041 (876–7815) ng/mL. Statistical analysis revealed that Nu.H3.1 levels significantly and positively correlated with cfDNA (r=0.67; p=0.0001), serum lactate (r=0.4; p=0.004), and SOFA scores (r=0.41; p=0.002). Furthermore, Nu.H3.1 demonstrated significant predictive performance for both 28-day mortality (AUC=0.68; 95% CI: 0.53–0.84; p=0.037) and the development of acute kidney injury (AKI) (AUC=0.74; 95% CI: 0.57–0.90; p=0.014). In conclusion, Nu.H3.1 serves as an independent predictor of adverse outcomes in septic shock, with established threshold values identifying patients at high risk for mortality and AKI. These findings suggest that Nu.H3.1 is a promising biomarker for clinical risk stratification and for substantiating indications for the extracorporeal elimination of toxic DNA-associated structures from the systemic circulation.
- Open Access
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 58-72
Prognostic value of histone H3.1-containing nucleosomes in septic shock: a prospective observational study
INTRODUCTION: Cell free DNA (cfDNA) is of considerable interest as a marker and pathogenesis factor in sepsis. Two processes are sources of cfDNA: cell death with the ingress of the contents of the cell nucleus into the bloodstream and the release of extracellular neutrophil traps (NETs). The marker of NETs formation is histone type 3.1. CfDNA and NETs in sepsis act in a dual role — they characterize the degree of cellular damage and the intensity of the inflammatory response, and at the same time they are etiological agents of these two processes. OBJECTIVE: This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing significant clinical events. MATERIALS AND METHODS: The prospective single-center observational study included 52 patients with septic shock (Sepsis-3 criteria), admitted to the intensive care unit. RESULTS: The total number of patients was n = 52, with the severity score SOFA 10 ± 4. The median concentration of Nu.H3.1 was 4658 ± 3962 ng/ml, cfDNA — 3041 (876–7815) ng/ml. The most significant correlations of Nu.H3.1 were recorded with the lactate level (rxy = 0.4; p = 0.004) and the SOFA scale (rxy = 0.41; p = 0.002). For Nu.H3.1, a significant association with 28-day mortality and AKI was determined. CONCLUSIONS: The study showed that the marker of NETs formation — the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream. Objective. This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing acute kidney injury (AKI) and 28-day mortality. Material and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria), admitted to the intensive care unit of the State Healthcare Institution "City Clinical Hospital named after S.S. Yudin" between August 2023 and May 2024. Results. The total number of patients included in the study was n=52 (64% men, 36% women) aged 52.1 ± 17.3 years, with the severity scores SOFA 10±4 and Apache II - 22±7 points, respectively. The median concentration of Nu.H3.1 was 4658± 3962 ng/ml, cfDNA - 3041 (876-7815.0) ng/ml. The correlation between cfDNA and Nu.H3.1 had a noticeable direct relationship (r xy = 0.67, p = 0.0001). The most significant correlations of Nu.H3.1 were recorded with the lactate level (r xy = 0.4, p = 0.004) and the SOFA scale (r xy = 0.41, p = 0.002). For Nu.H3.1, a significant association with 28-day mortality (AUC 0.68, 95% CI (0.53-0.84) p = 0.037) and AKI (AUC 0.74, 95% CI (0.57-0.90) p = 0.014) was determined. The OR for the development of AKI at a concentration of Nu.H3.1> 2731 ng / ml was 6.0 (95% CI: 1.6-26.0, p < 0.018), sensitivity, specificity - 67% and 75%, respectively. For 28-day mortality at a concentration of Nu.H3.1 > 2731 ng / ml, the OR was 4.4 (95% CI: 1.2-15.6; p = 0.03), sensitivity, specificity - 67 and 79%, respectively. Conclusion. The study showed that the marker of NETs formation – the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream.
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 58-72
Open AccessPrognostic value of histone H3.1-containing nucleosomes in septic shock: a prospective observational study
INTRODUCTION: Cell free DNA (cfDNA) is of considerable interest as a marker and pathogenesis factor in sepsis. Two processes are sources of cfDNA: cell death with the ingress of the contents of the cell nucleus into the bloodstream and the release of extracellular neutrophil traps (NETs). The marker of NETs formation is histone type 3.1. CfDNA and NETs in sepsis act in a dual role — they characterize the degree of cellular damage and the intensity of the inflammatory response, and at the same time they are etiological agents of these two processes. OBJECTIVE: This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing significant clinical events. MATERIALS AND METHODS: The prospective single-center observational study included 52 patients with septic shock (Sepsis-3 criteria), admitted to the intensive care unit. RESULTS: The total number of patients was n = 52, with the severity score SOFA 10 ± 4. The median concentration of Nu.H3.1 was 4658 ± 3962 ng/ml, cfDNA — 3041 (876–7815) ng/ml. The most significant correlations of Nu.H3.1 were recorded with the lactate level (rxy = 0.4; p = 0.004) and the SOFA scale (rxy = 0.41; p = 0.002). For Nu.H3.1, a significant association with 28-day mortality and AKI was determined. CONCLUSIONS: The study showed that the marker of NETs formation — the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream. Objective. This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing acute kidney injury (AKI) and 28-day mortality. Material and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria), admitted to the intensive care unit of the State Healthcare Institution "City Clinical Hospital named after S.S. Yudin" between August 2023 and May 2024. Results. The total number of patients included in the study was n=52 (64% men, 36% women) aged 52.1 ± 17.3 years, with the severity scores SOFA 10±4 and Apache II - 22±7 points, respectively. The median concentration of Nu.H3.1 was 4658± 3962 ng/ml, cfDNA - 3041 (876-7815.0) ng/ml. The correlation between cfDNA and Nu.H3.1 had a noticeable direct relationship (r xy = 0.67, p = 0.0001). The most significant correlations of Nu.H3.1 were recorded with the lactate level (r xy = 0.4, p = 0.004) and the SOFA scale (r xy = 0.41, p = 0.002). For Nu.H3.1, a significant association with 28-day mortality (AUC 0.68, 95% CI (0.53-0.84) p = 0.037) and AKI (AUC 0.74, 95% CI (0.57-0.90) p = 0.014) was determined. The OR for the development of AKI at a concentration of Nu.H3.1> 2731 ng / ml was 6.0 (95% CI: 1.6-26.0, p < 0.018), sensitivity, specificity - 67% and 75%, respectively. For 28-day mortality at a concentration of Nu.H3.1 > 2731 ng / ml, the OR was 4.4 (95% CI: 1.2-15.6; p = 0.03), sensitivity, specificity - 67 and 79%, respectively. Conclusion. The study showed that the marker of NETs formation – the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream.
- Open Access
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 73-85
Combined extracorporeal therapy with plasma exchange and hemoadsorbtion in septic shock: a randomized controlled study
INTRODUCTION: The consistently high mortality rate associated with septic shock leads to the search for new treatment strategies. OBJECTIVE: The aim of our study was to analyze the efficacy and safety of the combined use of plasma exchange and hemosorbtion in septic shock. MATERIALS AND METHODS: A total of 64 patients with septic shock who were hospitalized in the ICU of the S.S. Yudin Hospital in Moscow from January 2023 to January 2024 were prospectively examined. The combined extracorporeal therapy group included patients who underwent two combinations of procedures depending on the level of endotoxinactivity (endotoxin activity assay — EAA): with EAA greater than 0.6 — plasma exchange + LPS hemosorbtion, with EAA less than 0.6 — plasma exchange + cytokine hemosorption. The controlgroup included patients with standard sepsis therapy. Clinical and laboratory parameters, duration and outcomes of intensive care were recorded. RESULTS: The study group (ET, n = 31), compared with the control group (n = 33), was characterized by a significant (p < 0.05) reduction of organ disfunction according to the Sequential Organ Failure Assessment, and Acute Physiology and Chronic Health Evaluation II, scales, a decrease of systemic inflammation markers, and an increase of IgG level within 72 hours after inclusion in the study. Hospital mortality was lower in the ET group than in the control group 32 and 58 %, respectively: OR 0.35; 95% CI 0.12–0.98; p = 0.023. CONCLUSIONS: Combined extracorporeal therapy is an effective treatment strategy for septic shock, improving the results of its intensive care.
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 73-85
Open AccessCombined extracorporeal therapy with plasma exchange and hemoadsorbtion in septic shock: a randomized controlled study
INTRODUCTION: The consistently high mortality rate associated with septic shock leads to the search for new treatment strategies. OBJECTIVE: The aim of our study was to analyze the efficacy and safety of the combined use of plasma exchange and hemosorbtion in septic shock. MATERIALS AND METHODS: A total of 64 patients with septic shock who were hospitalized in the ICU of the S.S. Yudin Hospital in Moscow from January 2023 to January 2024 were prospectively examined. The combined extracorporeal therapy group included patients who underwent two combinations of procedures depending on the level of endotoxinactivity (endotoxin activity assay — EAA): with EAA greater than 0.6 — plasma exchange + LPS hemosorbtion, with EAA less than 0.6 — plasma exchange + cytokine hemosorption. The controlgroup included patients with standard sepsis therapy. Clinical and laboratory parameters, duration and outcomes of intensive care were recorded. RESULTS: The study group (ET, n = 31), compared with the control group (n = 33), was characterized by a significant (p < 0.05) reduction of organ disfunction according to the Sequential Organ Failure Assessment, and Acute Physiology and Chronic Health Evaluation II, scales, a decrease of systemic inflammation markers, and an increase of IgG level within 72 hours after inclusion in the study. Hospital mortality was lower in the ET group than in the control group 32 and 58 %, respectively: OR 0.35; 95% CI 0.12–0.98; p = 0.023. CONCLUSIONS: Combined extracorporeal therapy is an effective treatment strategy for septic shock, improving the results of its intensive care.
- 30 January 2026
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 14 (4)
The Role of Extracellular DNA Among Predictors of Hospital Mortality in Patients with Septic Shock
Introduction. Extracellular DNA (exDNA) is a well-known but poorly understood mediator of sepsis. The aim was to investigate the role of exDNA as an independent predictor of mortality and as a marker of unfavorable clinical phenotype for patients with septic shock. Material and methods. The patients over the age of 18 with septic shock (Sepsis-3 criteria) who were admitted to the intensive care unit of the S.S. Yudin City Clinical Hospital between August 2023 and May 2024 were included in a prospective observational study. Results. Total of fifty-two patients (64% men, 36% women) aged 52.1 ± 17.3 years, with severity of the condition on the SOFA score 10±4 and APACHE II score — 22±7 were included. The exDNA concentration was 3041 (876–7815.0) ng/ml. For exDNA, a significant (p=0,031) association with 28-day mortality was determined (AUC 0.69, 95% CI (0.54–0.84)), and a cut-off point >1893 ng/ml was identified, at which the OR of the hospital death corresponded to 4.3 (95% CI 1.3–15.1, p=0.03). The dependence of the risk of death on the concentration of exDNA (1893 ng/ml), estimated using the Mantel-Cox log-rank test, was statistically significant (p=0.028). The median survival time in the exDNA group >1893 ng/ml was 7 days, and for exDNA levels 1893 ng/ml in patients with septic shock were the level of mixed venous blood lactate (OR 2.0; 95% CI [1.02, 3.92], p=0.044) and SOFA score (OR 1.23; 95% CI [1.02, 1.47], p=0.029). Conclusion. The exDNA level is an independent predictor of mortality in septic shock. Its cut-off point of 1893 ng/ml could be considered as an indication for extracorporeal elimination of exDNA. Point of care laboratory markers of a significant increase in the blood concentration of exDNA were also identified and could be considered as a guide to an intensive care.
- 30 January 2026
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 14 (4)
The Role of Extracellular DNA Among Predictors of Hospital Mortality in Patients with Septic Shock
Introduction. Extracellular DNA (exDNA) is a well-known but poorly understood mediator of sepsis. The aim was to investigate the role of exDNA as an independent predictor of mortality and as a marker of unfavorable clinical phenotype for patients with septic shock. Material and methods. The patients over the age of 18 with septic shock (Sepsis-3 criteria) who were admitted to the intensive care unit of the S.S. Yudin City Clinical Hospital between August 2023 and May 2024 were included in a prospective observational study. Results. Total of fifty-two patients (64% men, 36% women) aged 52.1 ± 17.3 years, with severity of the condition on the SOFA score 10±4 and APACHE II score — 22±7 were included. The exDNA concentration was 3041 (876–7815.0) ng/ml. For exDNA, a significant (p=0,031) association with 28-day mortality was determined (AUC 0.69, 95% CI (0.54–0.84)), and a cut-off point >1893 ng/ml was identified, at which the OR of the hospital death corresponded to 4.3 (95% CI 1.3–15.1, p=0.03). The dependence of the risk of death on the concentration of exDNA (1893 ng/ml), estimated using the Mantel-Cox log-rank test, was statistically significant (p=0.028). The median survival time in the exDNA group >1893 ng/ml was 7 days, and for exDNA levels 1893 ng/ml in patients with septic shock were the level of mixed venous blood lactate (OR 2.0; 95% CI [1.02, 3.92], p=0.044) and SOFA score (OR 1.23; 95% CI [1.02, 1.47], p=0.029). Conclusion. The exDNA level is an independent predictor of mortality in septic shock. Its cut-off point of 1893 ng/ml could be considered as an indication for extracorporeal elimination of exDNA. Point of care laboratory markers of a significant increase in the blood concentration of exDNA were also identified and could be considered as a guide to an intensive care.
- Open Access
- 11 August 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 22 (4) , 31-42
A new technique for determining cell-free DNA levels and its diagnostic capabilities in patients with septic shock
Introduction. Multiple studies were shown significant role of cell-free DNA (cfDNA) as a marker and mediator of the septic process. Excessive formation of cfDNA is associated with adverse clinical events, which allows to consider this structure as a potential target for therapy.The objective was to study the level of cell-free DNA in patients with septic shock, to evaluate the correlation of the cfDNA level with clinical and laboratory data of patients, and the incidence of acute kidney injury and mortality.Materials and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria) admitted to the intensive care unit of the Moscow City Clinical Hospital named after S. S. Yudin of the Health Department of Moscow from August 2023 to May 2024.Results. The final number of patients included in the study was n = 52 (64% of men and 36% of women) aged 52.1 ± 17.3 years, with a severity score according to SOFA 10 ± 4 and Apache II 22 ± 7 points, respectively. The concentration of cfDNA was 3041 (876–7815.0) ng/ml. Correlation analysis revealed associations of various directions with clinical and laboratory data, the most significant was a moderately positive correlation with the level of lactate (rxy = 0.49, p < 0.0001) and creatinine (rxy = 0.42, p < 0.002). ROC curve analysis showed an association between the level of cfDNA and 28-day mortality (area under the curve 0.69, AUC 95% confidence interval (CI) (0.54–0.84), p = 0.031; cut off level – 1893 ng/ml; sensitivity – 72.2% and specificity – 62.5%). Conclusion. The study found that cfDNA had diagnostic value in septic shock, and the level of cfDNA correlated with clinical diagnostic data and significant clinical events in patients with septic shock.
- 11 August 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 22 (4) , 31-42
Open AccessA new technique for determining cell-free DNA levels and its diagnostic capabilities in patients with septic shock
Introduction. Multiple studies were shown significant role of cell-free DNA (cfDNA) as a marker and mediator of the septic process. Excessive formation of cfDNA is associated with adverse clinical events, which allows to consider this structure as a potential target for therapy.The objective was to study the level of cell-free DNA in patients with septic shock, to evaluate the correlation of the cfDNA level with clinical and laboratory data of patients, and the incidence of acute kidney injury and mortality.Materials and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria) admitted to the intensive care unit of the Moscow City Clinical Hospital named after S. S. Yudin of the Health Department of Moscow from August 2023 to May 2024.Results. The final number of patients included in the study was n = 52 (64% of men and 36% of women) aged 52.1 ± 17.3 years, with a severity score according to SOFA 10 ± 4 and Apache II 22 ± 7 points, respectively. The concentration of cfDNA was 3041 (876–7815.0) ng/ml. Correlation analysis revealed associations of various directions with clinical and laboratory data, the most significant was a moderately positive correlation with the level of lactate (rxy = 0.49, p < 0.0001) and creatinine (rxy = 0.42, p < 0.002). ROC curve analysis showed an association between the level of cfDNA and 28-day mortality (area under the curve 0.69, AUC 95% confidence interval (CI) (0.54–0.84), p = 0.031; cut off level – 1893 ng/ml; sensitivity – 72.2% and specificity – 62.5%). Conclusion. The study found that cfDNA had diagnostic value in septic shock, and the level of cfDNA correlated with clinical diagnostic data and significant clinical events in patients with septic shock.
- Open Access
- 31 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (8) , 5957
Association of cell-free DNA with the length of ulcerated plaque in the infarct-related artery and the myocardial infarct size among patients with ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention
Aim. To evaluate the changes of cell-free DNA (cfDNA) levels before and after percutaneous coronary intervention (PCI) in patients with ST-segment elevation acute coronary syndrome (STE-ACS). To identify associations of cfDNA concentration before and after PCI with complications and length of ulcerated plaque in patients with STE-ACS.Material and methods. This prospective single-center observational pilot study included 44 patients with STE-ACS admitted to the cardiac intensive care unit during the period of May-August 2023. In all patients, along with standard laboratory tests, cfDNA level was measured upon admission and 24 hours after PCI. Assessment of cfDNA associations before and after PCI was carried out in relation to following significant complications and conditions in STE-ACS patients: death, acute left ventricular failure (ALVF), acute heart failure (AHF), arrhythmia, number of stents implanted, number of segments with impaired local contractility, total stent length.Results. The mean age of the patients was 60,6±9,6 years, of which 74,6% were men. TIMI 0-1 flow was recorded in 93,2% of the subjects. The most common complications were cardiogenic shock (18,4%), arrhythmia (16,9%), AHF (13,6%), ALV (11,9%). Death was recorded in 8,5%. Implantation of 1 stent in PCI was performed in 75% of cases, while in the rest, 2 or more stents were implanted. The proportion of patients with impaired local contractility was 90%, the median stent length was 24,0 (20,0-50,0) mm. CfDNA level on admission did not differ from level after PCI 94,5 (78,3-155,5) ng/ml vs 115,0 (71,0-152,0), p=0,46. However, it significantly exceeded the cfDNA concentration from a group of healthy volunteers (78,0 (59,7-106,0), p=0,017). Characteristic curve showed significant relationships both for the concentration of cfDNA before (with implantation of 2 or more stents (AUC 0,71 with 95% confidence interval (CI) 0,56-0,86, p=0,039), stent length >24 mm (AUC 0,73 with 95% CI 0,58-0,89, p=0,009)) and after PCI (with the number of impaired local contractility segments (AUC 0,73 with 95% CI 0,57-0,89, p=0,014)). If the cfDNA level before PCI was >90 ng/ml, the risk of implantation of 2 or more stents per procedure increased by 5,4 times (odds ratio (OR) 5,4, 95% CI 1,11-28,93, p=0,044). The risk of a stent length >24 mm with pre-PCI cfDNA >107 ng/ml increased 9-fold (OR 9,0 with 95% CI 2,2-36,9, p=0,001), and the cfDNA level after PCI >105 ng/ml increased the risk of impaired local left ventricular (LV) contractility in 2 or more segments by 5 times (OR 5,0, 95% CI 1,23-20,3).Conclusion. In the studied group of patients with STE-ACS subject to intervention, the cfDNA concentration before PCI was associated with the implantation of ≥2 stents and the stent length (>24 mm). CfDNA level before PCI was associated with the number of segments of impaired local LV contractility (≥2).
- 31 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (8) , 5957
Open AccessAssociation of cell-free DNA with the length of ulcerated plaque in the infarct-related artery and the myocardial infarct size among patients with ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention
Aim. To evaluate the changes of cell-free DNA (cfDNA) levels before and after percutaneous coronary intervention (PCI) in patients with ST-segment elevation acute coronary syndrome (STE-ACS). To identify associations of cfDNA concentration before and after PCI with complications and length of ulcerated plaque in patients with STE-ACS.Material and methods. This prospective single-center observational pilot study included 44 patients with STE-ACS admitted to the cardiac intensive care unit during the period of May-August 2023. In all patients, along with standard laboratory tests, cfDNA level was measured upon admission and 24 hours after PCI. Assessment of cfDNA associations before and after PCI was carried out in relation to following significant complications and conditions in STE-ACS patients: death, acute left ventricular failure (ALVF), acute heart failure (AHF), arrhythmia, number of stents implanted, number of segments with impaired local contractility, total stent length.Results. The mean age of the patients was 60,6±9,6 years, of which 74,6% were men. TIMI 0-1 flow was recorded in 93,2% of the subjects. The most common complications were cardiogenic shock (18,4%), arrhythmia (16,9%), AHF (13,6%), ALV (11,9%). Death was recorded in 8,5%. Implantation of 1 stent in PCI was performed in 75% of cases, while in the rest, 2 or more stents were implanted. The proportion of patients with impaired local contractility was 90%, the median stent length was 24,0 (20,0-50,0) mm. CfDNA level on admission did not differ from level after PCI 94,5 (78,3-155,5) ng/ml vs 115,0 (71,0-152,0), p=0,46. However, it significantly exceeded the cfDNA concentration from a group of healthy volunteers (78,0 (59,7-106,0), p=0,017). Characteristic curve showed significant relationships both for the concentration of cfDNA before (with implantation of 2 or more stents (AUC 0,71 with 95% confidence interval (CI) 0,56-0,86, p=0,039), stent length >24 mm (AUC 0,73 with 95% CI 0,58-0,89, p=0,009)) and after PCI (with the number of impaired local contractility segments (AUC 0,73 with 95% CI 0,57-0,89, p=0,014)). If the cfDNA level before PCI was >90 ng/ml, the risk of implantation of 2 or more stents per procedure increased by 5,4 times (odds ratio (OR) 5,4, 95% CI 1,11-28,93, p=0,044). The risk of a stent length >24 mm with pre-PCI cfDNA >107 ng/ml increased 9-fold (OR 9,0 with 95% CI 2,2-36,9, p=0,001), and the cfDNA level after PCI >105 ng/ml increased the risk of impaired local left ventricular (LV) contractility in 2 or more segments by 5 times (OR 5,0, 95% CI 1,23-20,3).Conclusion. In the studied group of patients with STE-ACS subject to intervention, the cfDNA concentration before PCI was associated with the implantation of ≥2 stents and the stent length (>24 mm). CfDNA level before PCI was associated with the number of segments of impaired local LV contractility (≥2).
- Open Access
- 28 April 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (2) , 117-125
Left Atrial Thrombosis before Catheter Ablation or Cardioversion in Patients with Non-valvular Atrial Fibrillation or Atrial Flutter: what Risk Score is Most Informative?
Aim. To compare different scores in assessment of risk of left atrial or its appendage thrombosis (LAAT) in patients with non-valvular atrial fibrillation (AF) or atrial flutter (AFL) undergoing transesophageal echocardiography before catheter ablation (CA) or cardioversion (CV).Material and methods. In retrospective, single-center, case-control study medical records of 1994 patients with non-valvular AF or AF from the period 2014-2019, who underwent transesophageal echocardiography before CA or elective CV, were analyzed. LAAT was detected in 33 of them. For the control group, 167 patients without LAAT were randomly selected from this database. CHADS2, CHA2DS2-VASc, R2CHADS2, R-CHA2DS2-VASc, R2CHA2DS2-VASc, CHA2DS2-VASc-RAF, mCHA2DS2-VASc, CHA2DS2-VASc-AFR, ATRIA scores were evaluated and compared as potential predictors of LAAT.Results. Mean age of studied patients (n=200) was 60.3±10.9, 55% of them were males. Most of patients had non-valvular AF (87,5%) and were assessed before CA (84,0%). All risk scores were associated with LAAT and CHA2DS2-VASc-RAF score was most informative [AUC 0.84; 95% confidence interval (CI) 0.76-0.91]. According to multivariate analysis in a logistic regression model among studied risk scores CHA2DS2-VASc-RAF score was the single independent predictor of LAAT [odds ratio (OR) 1.37; 95% CI 1.21-1.55; p=0.004). OR of LAAT among patients with CHA2DS2-VASc-RAF >3 was 12.8 (95% CI 3.75-43.9; p˂0.0001) with sensitivity, specificity, positive and negative predicting values 90.6%, 57.1%, 30.2% and 96.7% respectively.Conclusion. In the studied group of patients with non-valvular AF or AFL, without severe structural heart disease and severe concomitant diseases CHADS2, CHA2DS2-VASc, R2CHADS2, R-CHA2DS2-VASc, R2CHA2DS2-VASc, CHA2DS2-VASc-RAF, mCHA2DS2-VASc, CHA2DS2-VASc-AFR, ATRIA scores were associated with LAAT. CHA2DS2-VASc-RAF score was the most informative.
- 28 April 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (2) , 117-125
Open AccessLeft Atrial Thrombosis before Catheter Ablation or Cardioversion in Patients with Non-valvular Atrial Fibrillation or Atrial Flutter: what Risk Score is Most Informative?
Aim. To compare different scores in assessment of risk of left atrial or its appendage thrombosis (LAAT) in patients with non-valvular atrial fibrillation (AF) or atrial flutter (AFL) undergoing transesophageal echocardiography before catheter ablation (CA) or cardioversion (CV).Material and methods. In retrospective, single-center, case-control study medical records of 1994 patients with non-valvular AF or AF from the period 2014-2019, who underwent transesophageal echocardiography before CA or elective CV, were analyzed. LAAT was detected in 33 of them. For the control group, 167 patients without LAAT were randomly selected from this database. CHADS2, CHA2DS2-VASc, R2CHADS2, R-CHA2DS2-VASc, R2CHA2DS2-VASc, CHA2DS2-VASc-RAF, mCHA2DS2-VASc, CHA2DS2-VASc-AFR, ATRIA scores were evaluated and compared as potential predictors of LAAT.Results. Mean age of studied patients (n=200) was 60.3±10.9, 55% of them were males. Most of patients had non-valvular AF (87,5%) and were assessed before CA (84,0%). All risk scores were associated with LAAT and CHA2DS2-VASc-RAF score was most informative [AUC 0.84; 95% confidence interval (CI) 0.76-0.91]. According to multivariate analysis in a logistic regression model among studied risk scores CHA2DS2-VASc-RAF score was the single independent predictor of LAAT [odds ratio (OR) 1.37; 95% CI 1.21-1.55; p=0.004). OR of LAAT among patients with CHA2DS2-VASc-RAF >3 was 12.8 (95% CI 3.75-43.9; p˂0.0001) with sensitivity, specificity, positive and negative predicting values 90.6%, 57.1%, 30.2% and 96.7% respectively.Conclusion. In the studied group of patients with non-valvular AF or AFL, without severe structural heart disease and severe concomitant diseases CHADS2, CHA2DS2-VASc, R2CHADS2, R-CHA2DS2-VASc, R2CHA2DS2-VASc, CHA2DS2-VASc-RAF, mCHA2DS2-VASc, CHA2DS2-VASc-AFR, ATRIA scores were associated with LAAT. CHA2DS2-VASc-RAF score was the most informative.
- Open Access
- 25 April 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (5) , 3543
Novel scale for predicting thrombosis of the left atrium and its appendage before catheter ablation or cardioversion in patients with nonvalvular atrial fibrillation or atrial flutter
Aim. To study the potential of predicting thrombosis of the left atrium (LA) and/or LA appendage (LAA) before catheter ablation (CA) or elective cardioversion in patients with nonvalvular atrial fibrillation (NAF) or atrial flutter (AFL) using indicators available in routine practice.Material and methods. In this single-center retrospective study, the medical records of 1994 patients with nAF or AFL for the period 2014-2019 were analyzed, who underwent transesophageal echocardiography before CA or elective CV. LA/LAA thrombus was found in 33 (1,6%) patients. For the comparison group, 167 patients were randomly selected without LA/LAA thrombosis. Demographic, anamnestic, clinical, laboratory data, results of transthoracic echocardiography, as well as the CHA2DS2-VASc-RAF (CHA2DS2-VASc plus 2 points for an estimated glomerular filtration rate 7 days), 10 points for persistent AF).Results. The mean age of the patients was 60,3±10,9 years (men, 55%). There were more patients with NAF (87,5%), hospitalized for CV (84,0%). Multivariate analysis revealed that the severity of symptoms associated with arrhythmia was associated with the detection of a LA/LAA thrombus (odds ratio (OR) for EHRA class 3-4 14,29 at 95% confidence interval (CI): 3,3-61,8; pConclusion. When predicting LA/LAA thrombosis, detected during transesophageal echocardiography before CA or elective CV in patients with NAF or AFL who did not have a pronounced structural heart pathology and severe concomitant diseases, taking into account the severity of symptoms associated with arrhythmia and a reduced left ventricular ejection fraction (2DS2-VASc-RAF did not lead to an increase in the area under the characteristic curve, but made it possible to increase the OR of LA/LAA thrombosis detection by 2 times and increase the sensitivity, specificity, positive and negative predictive value.
- 25 April 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (5) , 3543
Open AccessNovel scale for predicting thrombosis of the left atrium and its appendage before catheter ablation or cardioversion in patients with nonvalvular atrial fibrillation or atrial flutter
Aim. To study the potential of predicting thrombosis of the left atrium (LA) and/or LA appendage (LAA) before catheter ablation (CA) or elective cardioversion in patients with nonvalvular atrial fibrillation (NAF) or atrial flutter (AFL) using indicators available in routine practice.Material and methods. In this single-center retrospective study, the medical records of 1994 patients with nAF or AFL for the period 2014-2019 were analyzed, who underwent transesophageal echocardiography before CA or elective CV. LA/LAA thrombus was found in 33 (1,6%) patients. For the comparison group, 167 patients were randomly selected without LA/LAA thrombosis. Demographic, anamnestic, clinical, laboratory data, results of transthoracic echocardiography, as well as the CHA2DS2-VASc-RAF (CHA2DS2-VASc plus 2 points for an estimated glomerular filtration rate 7 days), 10 points for persistent AF).Results. The mean age of the patients was 60,3±10,9 years (men, 55%). There were more patients with NAF (87,5%), hospitalized for CV (84,0%). Multivariate analysis revealed that the severity of symptoms associated with arrhythmia was associated with the detection of a LA/LAA thrombus (odds ratio (OR) for EHRA class 3-4 14,29 at 95% confidence interval (CI): 3,3-61,8; pConclusion. When predicting LA/LAA thrombosis, detected during transesophageal echocardiography before CA or elective CV in patients with NAF or AFL who did not have a pronounced structural heart pathology and severe concomitant diseases, taking into account the severity of symptoms associated with arrhythmia and a reduced left ventricular ejection fraction (2DS2-VASc-RAF did not lead to an increase in the area under the characteristic curve, but made it possible to increase the OR of LA/LAA thrombosis detection by 2 times and increase the sensitivity, specificity, positive and negative predictive value.
- Open Access
- 18 January 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (12) , 3443
Predictors of thrombosis of left atrium and its appendage before catheter ablation or cardioversion in patients with non-valvular atrial fibrillation or atrial flutter
Aim. To determine the incidence of left atrial (LA) and/or LA appendage (LAA) thrombosis in patients with non-valvular atrial fibrillation (AF) (NAF) or atrial flutter (AFL) on transesophageal echocardiography (TEE) before elective catheter ablation (CA) or cardioversion (CV) and characterize the predictors of LA/LAA thrombosis among the indicators available in the routine practice of cardiologists and general practitioners.Material and methods. In this retrospective, single-center, casecontrol study, the medical records of 1994 patients with NAF or AFL for the period 2014-2019, who underwent TEE before CA or elective CV, were analyzed. A thrombus in the LA/LAA was detected in 33 (1,6%) of them. For the comparison group, 167 patients were randomly selected without LA/LAA thrombosis. Demographic, anamnestic and clinical parameters, transthoracic echocardiography data, and laboratory results were analyzed as potential predictors of LA/LAA thrombosis.Results. Patients with LA/LAA thrombosis were older (mean age, 64,8±1,6 vs 59,4±10,8 (p=0,01), more often had persistent or longstanding persistent AF, hypertension, heart failure, enlarged LA, lower left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate, as well as more severe symptoms according to the modified European Heart Rhythm Association (EHRA) score and a higher CHA2DS2-VASc score (median, 4,0 vs 2,0; p=0,0001). Oral anticoagulants were taken by 88% of patients; there were no significant differences in the presence and composition of anticoagulant therapy between the groups. Functional class (FC) according to the modified EHRA score (odds ratio (OR), 5,4; 95% confidence interval (CI): 1,9814,96; p=0,001) and LVEF were independent predictors of LA/LAA thrombosis (OR, 0,87; 95% CI: 0,80-0,95; p=0,002). For EHRA class 3-4, the OR was 5,1; 95% CI: 2,3-11,4 (pConclusion. In the studied group of patients with NAF or AFL, without severe structural heart disease and severe concomitant diseases, most of whom received oral anticoagulants, LA/LAA thrombosis at TEE before elective CA or CV was detected in 1,6% of cases. Among the indicators available in routine medical practice, the severity of arrhythmia symptoms, assessed by the modified EHRA score, and lower LVEF were independent predictors of LA/LAA thrombosis.
- 18 January 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (12) , 3443
Open AccessPredictors of thrombosis of left atrium and its appendage before catheter ablation or cardioversion in patients with non-valvular atrial fibrillation or atrial flutter
Aim. To determine the incidence of left atrial (LA) and/or LA appendage (LAA) thrombosis in patients with non-valvular atrial fibrillation (AF) (NAF) or atrial flutter (AFL) on transesophageal echocardiography (TEE) before elective catheter ablation (CA) or cardioversion (CV) and characterize the predictors of LA/LAA thrombosis among the indicators available in the routine practice of cardiologists and general practitioners.Material and methods. In this retrospective, single-center, casecontrol study, the medical records of 1994 patients with NAF or AFL for the period 2014-2019, who underwent TEE before CA or elective CV, were analyzed. A thrombus in the LA/LAA was detected in 33 (1,6%) of them. For the comparison group, 167 patients were randomly selected without LA/LAA thrombosis. Demographic, anamnestic and clinical parameters, transthoracic echocardiography data, and laboratory results were analyzed as potential predictors of LA/LAA thrombosis.Results. Patients with LA/LAA thrombosis were older (mean age, 64,8±1,6 vs 59,4±10,8 (p=0,01), more often had persistent or longstanding persistent AF, hypertension, heart failure, enlarged LA, lower left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate, as well as more severe symptoms according to the modified European Heart Rhythm Association (EHRA) score and a higher CHA2DS2-VASc score (median, 4,0 vs 2,0; p=0,0001). Oral anticoagulants were taken by 88% of patients; there were no significant differences in the presence and composition of anticoagulant therapy between the groups. Functional class (FC) according to the modified EHRA score (odds ratio (OR), 5,4; 95% confidence interval (CI): 1,9814,96; p=0,001) and LVEF were independent predictors of LA/LAA thrombosis (OR, 0,87; 95% CI: 0,80-0,95; p=0,002). For EHRA class 3-4, the OR was 5,1; 95% CI: 2,3-11,4 (pConclusion. In the studied group of patients with NAF or AFL, without severe structural heart disease and severe concomitant diseases, most of whom received oral anticoagulants, LA/LAA thrombosis at TEE before elective CA or CV was detected in 1,6% of cases. Among the indicators available in routine medical practice, the severity of arrhythmia symptoms, assessed by the modified EHRA score, and lower LVEF were independent predictors of LA/LAA thrombosis.
- Open Access
- 2 June 2020
- Published by Remedium, Ltd. in Atherothrombosis
- No. 1,p. 56-70
Thrombus of left atrium and/or its appendage in nonvalvular atrial fibrillation: echocardiographic and laboratory risk factors, capabilities for prediction and correction
Тромбоз левого предсердия и/или его ушка при неклапанной фибрилляции предсердий: эхокардиографические и лабораторные факторы риска, возможности прогнозирования и коррекции
- 2 June 2020
- Published by Remedium, Ltd. in Atherothrombosis
- No. 1,p. 56-70
Open AccessThrombus of left atrium and/or its appendage in nonvalvular atrial fibrillation: echocardiographic and laboratory risk factors, capabilities for prediction and correction
Тромбоз левого предсердия и/или его ушка при неклапанной фибрилляции предсердий: эхокардиографические и лабораторные факторы риска, возможности прогнозирования и коррекции